Ptc Therapeutics (PTCT) Cash from Investing Activities (2012 - 2026)

Ptc Therapeutics' Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$122.6 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 70.96% year-over-year to -$122.6 million; the TTM figure through Jun 2026 stood at -$471.9 million (down 23.75% YoY), while the FY2025 annual figure was -$862.0 million, down 2050.98% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at -$122.6 million, down from -$93.7 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $267.7 million in Q4 2024, with the low at -$422.0 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is -$36.1 million (2023), against an average of -$51.1 million.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 383.54% in 2024, then sank 578.67% in 2025.
• Ptc Therapeutics' Cash from Investing Activities stood at $32.4 million in 2022, then slumped by 391.06% to -$94.4 million in 2023, then jumped by 383.54% to $267.7 million in 2024, then sank by 87.3% to $34.0 million in 2025, then sank by 460.37% to -$122.6 million in 2026.
• Business Quant data shows PTCT's Cash from Investing Activities at -$122.6 million in Q2 2026, -$93.7 million in Q1 2026, and $34.0 million in Q4 2025.